The fine needle aspiration (FNA) of cells infiltrating renal allografts has proven to be a useful and safe tool for monitoring renal graft outcome [1]. The recent availability of broad panels of murine monoclonal antibodies defining lymphocyte subsets has permitted the fine characterization of the profile of the FNA cell membrane. Thus, it has been shown that the onset of graft rejection is associated, in some cases, with the presence of large proportions of infiltrating cells that express the membrane antigen characteristic of suppressor cytotoxic lymphocytes (that is, OKT8 cells) [2, 31. It remains to be shown, however, whether these cells possess the functional capacities conesponding to this phenotype. Until now, this has been impossible due to the small number of cells recovered from FNA samples. The aim of this brief report is to describe a technique which allows the in vitro expansion of the lymphoid cell population contained in FNA samples in long-term cultures and thus the simultaneous analysis of their phenotypes and functions. Methods. Fine needle aspiration samples were obtained from six renal allograft recipients undergoing rejection. In all the patients the FNA was performed before the onset of antirejection treatment (that is, high dose corticotherapy). Freshly collected FNA samples were analyzed in parallel with blood samples drawn at the same moment from the same patients. In the present study only the aspirates containing high proportions of blastic mononuclear cells that were absent from peripheral blood were considered. Hemolysis of the red cells contaminating the cell samples was performed using the following .buffer: 8.29 g NH4C1, 37 mg disodium EDTA, and I g KHCO3 per liter, pH 7.3. Leukocytes were washed and recovered following a 10-mm centrifugation at 1500 rpm. The viable cells were counted by trypan blue dye exclusion, and cultured in round-bottomed microplates (Nunclon, Roskild, Sweden) (1 x iO to 2 x l0 cells per microwell in 0.2 ml). The number of cells recovered from FNA samples usually ranged from 5 x iO to 15 x i04 cells, depending on the patient. The conditioned medium (CM) used for culture was RPMI 1640 (GIBCO, Paisley, United Kingdom) supplemented with antibiotics, 50% crude supernatant containing significant levels of interleukin-2 (IL-2), 10% heatinactivated, fetal calf serum (FCS) (GIBCO, Paisley, United Kingdom), 5 x l0M mercaptoethanol and l%glutamine. The IL-2 containing supernatant was produced by stimulating normal human peripheral blood lymphocytes with phytohemagglutinin A (DIFCO, Detroit, Michigan, USA) for 48 hr as previously described [4]. The supernatants used to grow FNA cells contained approximately 0.7 to I U/ml of IL-2 activity (assessed by CTLL2 proliferation, see [5] for the definition of an IL-2 unit). After the initial 4 days of culture, the cells were fed every 48 to 72 hr by replacing half of the culture medium with fresh CM. Cell proliferation was regularly evaluated by means of cell counting with trypan blue dye, in parallel with 3H-thymidine incorporation. This latter method was particularly useful for the assessment of proliferation during the early days of culture. By day 4 of the culture, the FNA cells from all patients began to incorporate significant amounts of 3H-thymidine: patient 1: day 4,4177 cpm; day 5, 9042 cpm; day 6, 19335; patient 2: day 3, 548 cpm; day 4, 2353 cpm; day 5, 16506 cpm. Moreover, by days 7 to 11, depending on the patient, and approximately until day 20, the growth rate increased significantly with a doubling time of 6 hr (assessed by cell counting). Thereafter, the proliferation decreased with a doubling time close to 12 hr. All cultures were successfully maintained for 30 to 45 days. Phenotypic analysis of cultured cells was performed at regular intervals by means of an indirect immunofluorescence microtest, described by Cashman et al [6], using the OKT series of monoclonal antibodies. The antibodies used were OKT3 (IgG2a), OKT4 (IgG2b), and OKT8 (IgG2a) which react, respectively, with mature peripheral human T cells, helper/inducer T cells and suppressor/cytotoxic T cells [7]. In